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p<0.01). Macrophage derived cytokines/chemokines; hu-
man IL-6, IL-8, CCL2, CXCL10, sCD40L were signiﬁcantly
increased in the serum from mice with liver ﬁbrosis. Flow-
cytometry analysis showed that the CD68+ cells were
CD14lowCD16+CCR6+HLADR+ positive.
Conclusion: We show that the combination of cyclophos-
phamide and 200cGy TBI with a low number of G-CSF-
mobilized human PBMCs (1x106) leads to portal inﬂam-
mation and bile duct damage which mimic liver pathology
in patients with human cGvHD. Human CD68+ macro-
phages appear to cause liver ﬁbrosis in this model. This
may serve as an important pre-clinical model of the severe
form of cGvHD.404
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Introduction: Allogeneic transplantation is the only curative
option for patients with high risk hematologic malignancies.
Only one third of them have an HLA identical sibling donor
and around 60-70% will ﬁnd an unrelated donor, that’s why
HAPLO-HSCT offers a therapeutic option to most of these
patients with the advantages of quick availability, easy pro-
gramation and logistics, and a committed donor. Bone
marrow (BM) or peripheral blood stem cells (PBSC) could be
used as graft source but it’s not established if any of them
offer signiﬁcant advantages.
Patients and Methods: We retrospectively evaluated the
results of HAPLO-HSCT with reduced conditioning regimens
and GVHD prophylaxis based on PT-CY (50 mg/kg on days +3
and +4) and a calcineurin inhibitor plus mycophenolate from
day +5 performed in GETH centers, with focus on the graft
source.
Results: FromDec-2007, 118 HAPLO-HSCT have been done in
17 centers. Median agewas 36 years (16-67), 64% weremales
and all were in advanced phases of their disease or presented
high risk features (Hodgkin’s 43%, AML/ALL/MDS 36%, NHL/
myeloma/others 21%). Previous HSCT had been employed in
64% (autologous 66, allogeneic 19), and in 36% the HAPLO-
HSCT was their ﬁrst transplant. Disease status at HAPLO-
HSCT was CR in 44%, with persistent disease in 55%. BM was
the graft source in 48 patients (41%) and PBSC in 70 (59%),
non T-cell depleted in all cases. The haploidentical donor was
the patient’s mother (28%), father (10%), siblings (44%) or
offspring (18%). Baltimore’s reduced conditioning (RIC)including 200cGy was employed in 15% and RIC based on IV
busulfan in 85% (44% with 3.2 mg/kg on day -2 (BUX1), and
days -3 and -2 (BUX2) in 41%). Median neutrophils engraft-
ment was reached at day +18 (13-45) and platelets >20K at
day +26 (11-150), without signiﬁcant differences (NS) be-
tween BM and PBSC.
Main toxic complications were grade II-III mucositis in
36%, febrile neutropenia in 75% and CMV reactivations in
62%. Transplant related mortality rate (TRM) at 1 year was
19% with BM vs 23% with PBSC (NS). Day +100 grade II-IV
acute GVHD cumulative incidence (CI) was 46% vs 48%, and
grade III-IV was 15% and 10% with BM and PBSC respectively.
Chronic GVHD CI at 1 year was 40% vs 24% (NS), being
extensive in 16% and 9% (NS) respectively. No differences in
acute or chronic GvHD CI were seen when comparing BM
against PBSC. After a median follow-up of 10 months (3-61),
estimated event-free survival (EFS) and overall survival (OS)
at 18 months were 41% and 59% respectively. CI of relapse or
progression was 29%. No signiﬁcant differences in TRM, EFS,
OS and relapse incidence were detected between BM and
PBSC.
Conclusions: HAPLO-HSCT with PT-CY in the treatment of
high risk hematologic malignancies, offers long-lasting re-
missions with manageable toxicity and GVHD, employing
either BM or PBSC that render similar results as graft
source.405
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Patients and Methods: This is a retrospective analysis of
patients with thalassaemia major who underwent allogeneic
stem cell transplantation at CMC Hospital, Vellore India
between November 2009 and December 2013 using a
uniform Fludarabine/Treosulfan/Thiotepa based condition-
ing regimen. Graft source was either unmanipulated bone
marrow or G-CSF primed peripheral blood stem cells (PBSC).
Donors were either HLA identical sibling/family or unrelated
donors. Whole blood chimerismwas performed using VNTRs
on Day 30, 60-90, and subsequently based upon physician
decision. >95% donor cells was considered as complete
chimerism. If there was a drop in chimerism, reduction of
immunosuppression and donor lymphocyte infusion (DLI)
was considered.
Results: 132 patients underwent HSCT for thalassemia major
during this period of which 120 who survived more than 4
weeks post HSCT were evaluable for chimerism. There were
70 males and 50 females with a median age was 9.3 years
(range: 3 e 21). Majority had Lucarelli Class III thalassaemia.
113 (94.1%) hadmatched sibling or family donors while 7 had
unrelated donors. Graft source was predominantly PBSC in
97 (80.8%). At day 28 post HSCT, 97 (80.8%) had complete
chimerism (CC) while graft rejection occurred in 3 and 20
(16.6%) had mixed chimerism (MC) (Level 1 in 12, level 2 and
level 3 had 4 each). Of the 97 patients with CC, 23 (23.7%)
developed mixed chimerism between 2-4 months after
HSCT. This included level 1 MC in 14, level 2 MC in 7 and level
3 MC in 2. The overall incidence of MC occurring at any time
post HSCT was 35.8%. Tapering and cessation of cyclosporine
